- Home
- TNXP
as 12-20-2024 4:00pm EST
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | CHATHAM |
| Market Cap: | 19.5M | IPO Year: | N/A |
| Target Price: | $53.50 | AVG Volume (30 days): | 202.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.12 - $14.08 | Next Earning Date: | 11-12-2024 |
| Revenue: | $11,291,000 | Revenue Growth: | 183.05% |
| Revenue Growth (this year): | 64.71% | Revenue Growth (next year): | 24.49% |
Latest Tonix Pharmaceuticals Holding Corp. News
TNXP Breaking Stock News: Dive into TNXP Ticker-Specific Updates for Smart Investing
MT Newswires
6 days ago
Tonix Pharmaceuticals Shares Jump After FDA Accepts NDA for Fibromyalgia Drug
GlobeNewswire
6 days ago
Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia
GlobeNewswire
6 days ago
Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights
ACCESSWIRE
14 days ago
Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers
GlobeNewswire
20 days ago
Tonix Pharmaceuticals Announces Expansion of Leadership Team with Two Strategic Hires
Zacks Small Cap Research
20 days ago
TNXP: NDA Filed for TNX-102 SL in Fibromyalgia…
GlobeNewswire
a month ago
Tonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference
GlobeNewswire
a month ago
Tonix Pharmaceuticals to Present at the Winter 2024 Investor Summit Virtual
Compare TNXP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TNXP Tonix Pharmaceuticals Holding Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.